Logo Image

Andrew Coelho, PharmD

Articles by Andrew Coelho, PharmD

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

ByAlan Gabot, PharmD,Pavel Lavitas, PharmD, BCPS,Rachel Bacon, PharmD, MPH,Thomas C. Pomfret, PharmD, MPH, BCPS,Mckenzie Taylor, PharmD, MS,Andrew Coelho, PharmD,Bonnie C. Greenwood, PharmD, BCPS,Caroline J. Alper, MD,Karen M. Clements, ScD,Kimberly Lenz, PharmD, MBA

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.

Latest Updated Articles